Treatment Sequencing and Unmet Needs in HR+/HER2-Low Metastatic Breast Cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, discuss treatment sequencing practices and ongoing challenges in patients with HR+/HER2-low breast cancer.
Video content above is prompted by the following questions:
- For patients who no longer benefit from prior endocrine therapy, what is your current approach to treatment sequencing in HR+/HER2-low metastatic breast cancer?
- What are some unmet needs and ongoing challenges in patients with HR+/HER2-low breast cancer?
T-DXd Use in HER2+ Breast Cancer Influenced by Site of Metastases and AE Monitoring
October 21st 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
